Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

121. Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: a randomised controlled proof-of-concept trial. Full Text available with Trip Pro

Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: a randomised controlled proof-of-concept trial. The APPLE COPD-ICON2 trial is a prospective 2×2 factorial, double-blinded proof-of-concept randomised controlled trial targeting patients with chronic obstructive pulmonary disease (COPD) without prior history of cardiovascular disease. The primary goal of this trial is to investigate if treatment with antiplatelet (...) recruited with mean age of 67.5 years; 47.5% patients were male. The per-protocol ASPI test response rate to aspirin was 68.3% (95% CI 52.3-80.9%). The per-protocol ADP test response rate to ticagrelaor was 68.8% (95% CI 50.4-82.6%). Platelet response to antiplatelet therapy with aspirin and ticagrelor was not observed in nearly one-third of COPD patients without prior history of cardiovascular disease. These findings support the high pro-thrombotic milieu and the need for further research to determine

2019 ERJ open research Controlled trial quality: predicted high

122. COPD exacerbation: no systematic use of antibiotics

of moderate aggravation in patients with chronic obstructive pulmonary disease (COPD), it is preferable to prescribe antibiotics as a first-line treatment only when the suspicion of bacterial infection is reinforced by an increase in sputum purulence. Patients with chronic obstructive pulmonary disease (COPD) are subject to exacerbations of their disease, i.e. episodes of prolonged aggravation. The known causes are mainly viral and bacterial infections. Some exacerbations justify hospitalisation: severe (...) amoxicillin is not appropriate. Whether or not antibiotic treatment is chosen, patient monitoring is useful during the first few days to detect any aggravation that warrants a change in treatment. ©Prescrire 1 January 2019 Share Share Download the full review. See also: Chronic obstructive pulmonary disease. Useful medications for patients with recurrent symptoms Prescrire Int 2016 ; 25 (176) : 272-27 | | | Prescrire Your change of address has been received and will be processed promptly

2019 Prescrire

123. Revefenacin (Yupelri) - To treat patients with chronic obstructive pulmonary disease (COPD)

Revefenacin (Yupelri) - To treat patients with chronic obstructive pulmonary disease (COPD) Drug Approval Package: Yupelri (revefenacin) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Yupelri (revefenacin) Company: Theravance Biopharma Ireland Limited Application Number: 210598 Approval Date: 11/09/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling

2019 FDA - Drug Approval Package

124. Clinical validation of a risk scale for serious outcomes among patients with chronic obstructive pulmonary disease managed in the emergency department Full Text available with Trip Pro

Clinical validation of a risk scale for serious outcomes among patients with chronic obstructive pulmonary disease managed in the emergency department The Ottawa chronic obstructive pulmonary disease (COPD) Risk Scale (OCRS), which consists of 10 criteria, was previously derived to identify patients in the emergency department with COPD who were at high risk for short-term serious outcomes. We sought to validate, prospectively and explicitly, the OCRS when applied by physicians in the emergency (...) department.We conducted this prospective cohort study involving patients in the emergency departments at 6 tertiary care hospitals and enrolled adults with acute exacerbation of COPD from May 2011 to December 2013. Physicians evaluated patients for the OCRS criteria, which were recorded on a data form along with the total risk score. We followed patients for 30 days and the primary outcome, short-term serious outcomes, was defined as any of death, admission to monitored unit, intubation, noninvasive

2019 EvidenceUpdates

125. Comparing the effects of upper limb and breathing exercises on six-minute walking distance among patients with chronic obstructive pulmonary disease: a three-group randomized controlled clinical trial. Full Text available with Trip Pro

Comparing the effects of upper limb and breathing exercises on six-minute walking distance among patients with chronic obstructive pulmonary disease: a three-group randomized controlled clinical trial. Physical exercise can improve patient outcomes and reduce hospitalization and mortality rates among subjects with chronic obstructive pulmonary disease. This study aimed to compare the effects of upper limb and breathing exercises on six-minute walking distance among these patients.This three (...) significant (p > 0.05).Upper limb exercise is more effective than breathing exercise in increasing walking distance among patients with chronic obstructive pulmonary disease. Therefore, upper limb exercise can be used as a safe, simple, and inexpensive rehabilitation technique for these patients.

2019 Advances in respiratory medicine Controlled trial quality: uncertain

126. Impact of a Clinical Pharmacist Intervention on Medicine Costs in Patients with Chronic Obstructive Pulmonary Disease in India. Full Text available with Trip Pro

Impact of a Clinical Pharmacist Intervention on Medicine Costs in Patients with Chronic Obstructive Pulmonary Disease in India. Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality, especially in low- and middle-income countries (LMICs) such as India. Medicine costs are a key issue in LMICs, with typically high patient co-payments. In addition, pharmacists are underutilised in LMICs, including India. However, pharmacist-led educational interventions may (...) at baseline increased with disease severity, from a maximum of US$29.46 for those with mild COPD to US$63.28 for those with very severe COPD. Substantial savings in medical costs were achieved with the pharmacist-led programme, to a maximum of US$20.49 over 6 months for very severe patients. This equates to a reduction of 30.6% in medicine costs (p < 0.001), reduced to 26.1% when pharmacists' time (US$3.00/patient) was included.There could be a key role for pharmacists as educators for COPD patients

2019 PharmacoEconomics - open Controlled trial quality: uncertain

127. A randomised controlled trial to investigate the use of high-frequency airway oscillations as training to improve dyspnoea in COPD. Full Text available with Trip Pro

A randomised controlled trial to investigate the use of high-frequency airway oscillations as training to improve dyspnoea in COPD. Chronic obstructive pulmonary disease (COPD) is characterised by expiratory flow limitation resulting in symptomatic dyspnoea, sputum retention and ventilation heterogeneity. Changes in breathing mechanics affect the ability of respiratory muscles to respond to the ventilatory demands, increasing the sensation of dyspnoea. A high-frequency airway oscillating device (...) and oscillations for combined training. Those receiving the sham device will follow the same protocol; however, the mechanism of action will be removed from the device. Improvements in the Chronic Respiratory Questionnaire-Dyspnoea domain will be the primary outcome measure. Secondary outcomes will explore respiratory muscle function, health-related quality of life, exercise capacity and physical activity. The Lung Clearance Index will be an exploratory outcome. Outcomes will be explored using the most

2019 ERJ open research Controlled trial quality: predicted high

128. Temporal Trends Of Pharmacologic Therapies For Patients With Chronic Obstructive Pulmonary Disease In Alberta, Canada Full Text available with Trip Pro

Temporal Trends Of Pharmacologic Therapies For Patients With Chronic Obstructive Pulmonary Disease In Alberta, Canada Temporal Trends Of Pharmacologic Therapies For Patients With Chronic O | COPD Javascript is currently disabled in your browser. Several features of this site will not function whilst javascript is disabled. open access to scientific and medical research Journal Email Alerts About Dove Press Open access peer-reviewed scientific and medical journals. Open Access Dove Medical Press (...) Correspondence: Dat T Tran Institute of Health Economics, #1200 – 10405 Jasper Avenue, Edmonton, Alberta T5J 3N4, Canada Tel +1 780 448 4881 Fax +1 780 448 0018 Email dttran@ualberta.ca Objectives: To describe the trends in pharmacologic treatment for patients newly diagnosed with chronic obstructive pulmonary disease (COPD) in Alberta, Canada. Methods: We linked Alberta health databases to identify patients aged ≥35 years with incident COPD between April 2010 and March 2017. Incident cases were defined

2019 Institute of Health Economics

129. Chronic obstructive pulmonary disease: Theophylline

Chronic obstructive pulmonary disease: Theophylline Theophylline | Prescribing information | Chronic obstructive pulmonary disease | CKS | NICE Search CKS… Menu Theophylline Chronic obstructive pulmonary disease: Theophylline Last revised in November 2019 Theophylline How should theophylline be prescribed? Prescribe theophylline by brand name as there are bioavailablility differences between brands — if discharged from hospital on theophylline the brand of on which they were stabilized (...) as an inpatient should be maintained. Plasma-theophylline concentration is increased in heart failure, hepatic impairment, and in viral infections. Plasma-theophylline concentration is decreased in smokers, and by alcohol consumption. Differences in the half-life of theophylline are important because the toxic dose is close to the therapeutic dose. [ ; ] What dose of theophylline should I prescribe for COPD? Theophylline Nuelin SA® modified release tablets: Nuelin SA® 175 tablets — for reversible airways

2019 NICE Clinical Knowledge Summaries

130. Chronic obstructive pulmonary disease: Scenario: End-stage chronic obstructive pulmonary disease

disease and malignancy. Tools, such as those from the are available help healthcare professionals identify people who are likely to be approaching the end of their life. Basis for recommendation The information on end-stage COPD is based on clinical guidelines COPD-X: concise guide for primary care [ ] and Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019 repor t [ ] and expert (...) deterioration — this information should be made available to out-of-hours and ambulance services. Support of their family/carers. Needs for psychological and spiritual care. Copies of advance care plans should be available in the person’s home or with them if admitted to hospital, care home or hospice. For more information on advance care planning, see the section on in the CKS topic on . The usefulness of advance decisions in chronic obstructive pulmonary disease (COPD) may be limited because: It is rarely

2019 NICE Clinical Knowledge Summaries

131. Chronic obstructive pulmonary disease: Scenario: COVID-19 Management

taking their regular inhaled and oral medicines in line with their individualised chronic obstructive pulmonary disease (COPD) self-management plan. This includes those with COVID‑19, or who are suspected of having it. Keep their self-management plan up to date and remind them that online video resources on correct inhaler technique are available. At every interaction with a patient, be alert for new or increased issues with mental health and wellbeing, particularly anxiety and depression. Find out (...) such as: Using equipment in a well-ventilated room. Using equipment away from other family members if possible. Basis for recommendation These recommendations are based on COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD) [ ]. The advice for people to continue with their regular self-management plan is to ensure that their COPD is as stable as possible. The recommendation to only prescribe 30 days of medication is based on pragmatic advice from NICE

2019 NICE Clinical Knowledge Summaries

132. Chronic obstructive pulmonary disease: Oral corticosteroids

Chronic obstructive pulmonary disease: Oral corticosteroids Oral corticosteroids | Prescribing information | Chronic obstructive pulmonary disease | CKS | NICE Search CKS… Menu Oral corticosteroids Chronic obstructive pulmonary disease: Oral corticosteroids Last revised in November 2019 Oral corticosteroids What issues need to be considered when prescribing oral corticosteroids? Short courses of oral corticosteroids are commonly used for acute exacerbations of chronic obstructive pulmonary (...) disease (COPD). Maintenance use of oral corticosteroid therapy in COPD is not normally recommended. However, some people with advanced COPD may require maintenance oral corticosteroids when these cannot be withdrawn after an exacerbation. In these cases, the dose of oral corticosteroids should be kept as low as possible. People on long-term corticosteroid treatment should carry a steroid treatment card and be monitored for osteoporosis/given appropriate prophylaxis. For detailed prescribing

2019 NICE Clinical Knowledge Summaries

133. Chronic obstructive pulmonary disease: Muscarinic antagonists

Chronic obstructive pulmonary disease: Muscarinic antagonists Muscarinic antagonists | Prescribing information | Chronic obstructive pulmonary disease | CKS | NICE Search CKS… Menu Muscarinic antagonists Chronic obstructive pulmonary disease: Muscarinic antagonists Last revised in November 2019 Muscarinic antagonists Muscarinic antagonists (also called antimuscarinic bronchodilators) cause bronchodilation by blocking the bronchoconstrictor effect of acetylcholine on muscarinic receptors (...) in airway smooth muscle. Ipratropium is a short-acting muscarinic antagonist (SAMA) which can be used for short-term relief in mild COPD in people who are not using a long-acting antimuscarinic drug. It has a slower onset of action than SABAs with maximal effect occurring 30–60 minutes after use — duration of action is 3–6 hours. Long-acting muscarinic antagonists (LABAs) such as tiotropium have prolonged binding to muscarinic receptors which lengthens the duration of bronchodilator effect. Aclidinium

2019 NICE Clinical Knowledge Summaries

134. Chronic obstructive pulmonary disease: Scenario: Acute exacerbation of chronic obstructive pulmonary disease

for primary care [ ], Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline [ ] and Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019 repor t [ ]. Recommendation on oxygen administration are taken from the British Thoracic Society guideline BTS guideline for oxygen use in adults in healthcare and emergency settings [ ] which states (...) [ ], and the clinical guidelines COPD-X: concise guide for primary care [ ] and Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019 repor t [ ]. Short-acting bronchodilators — clinical guidance from NICE, GOLD and the Lung Foundation Australia is in agreement on increasing the dose or frequency of use of inhaled medication for acute exacerbations of COPD. NICE did not review the evidence

2019 NICE Clinical Knowledge Summaries

135. Chronic obstructive pulmonary disease: Scenario: Stable chronic obstructive pulmonary disease

to a respiratory specialist may also be required to assess the need for: Oxygen therapy. Long-term non-invasive ventilation. Nebulizer therapy or long-term oral corticosteroids. Lung surgery (for example, for a person with bullous lung disease who is still symptomatic on maximal treatment). Basis for recommendation The recommendations on when to refer a person with stable chronic obstructive pulmonary disease (COPD) are based on the clinical guidelines Diagnosis and initial treatment of asthma, COPD and asthma (...) -COPD overlap [ ], COPD-X: concise guide for primary care [ ], Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019 report [ ], and Chronic obstructive pulmonary disease in over 16s: diagnosis and management [ ]. The GINA and GOLD guideline on asthma-COPD overlap recommends referral for specialist input as the outcome is often worse for asthma-COPD overlap then for either condition

2019 NICE Clinical Knowledge Summaries

136. Systematic review of platforms used for remote monitoring of vital signs in patients with hypertension, asthma and / or chronic obstructive pulmonary disease Full Text available with Trip Pro

Systematic review of platforms used for remote monitoring of vital signs in patients with hypertension, asthma and / or chronic obstructive pulmonary disease Systematic Review of Platforms Used for Remote Monitoring of Vital Signs in Patients With Hypertension, Asthma and/or Chronic Obstructive Pulmonary Disease - IEEE Journals & Magazine IEEE Account Purchase Details Profile Information Need Help? US & Canada: +1 800 678 4333 Worldwide: +1 732 981 0060 A not-for-profit organization, IEEE

2019 IEEE Access

138. Effects of the clearing the lung and dissipating phlegm method in the treatment of acute exacerbation of chronic obstructive pulmonary disease: A systematic review and meta-analysis Full Text available with Trip Pro

the lung and dissipating phlegm method in the treatment of acute exacerbation of chronic obstructive pulmonary disease: A systematic review and meta-analysis. World J Tradit Chin Med [serial online] 2019 [cited 2021 Feb 2];5:61-9. Available from: Introduction The 2018 Global Initiative for Chronic Obstructive Lung Disease (COLD) has re-defined the chronic obstructive pulmonary disease (COPD) as a common, preventable, and treatable disease that is characterized by persistent respiratory symptoms (...) and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases. According to the estimations by the Burden of Obstructive Lung Diseases and other large scale epidemiological studies, there were a total of 384 million patients with COPD in 2010, with a prevalence of 11.7% globally. With the smoking population in developing countries and the aging population in developed countries increasing and the deteriorating

2019 World Journal of Traditional Chinese Medicine

139. Educational component in rehabilitation programs for persons with chronic obstructive pulmonary disease: a systematic review Full Text available with Trip Pro

Educational component in rehabilitation programs for persons with chronic obstructive pulmonary disease: a systematic review Educational component in rehabilitation programs for persons with chronic obstructive pulmonary disease: a systematic review eISSN: 1734-4948 ISSN: 0860-6161 Advances in Rehabilitation Search 4/2019 vol. 33 Share: Copy url: Share: abstract: Review paper Educational component in rehabilitation programs for persons with chronic obstructive pulmonary disease: a systematic (...) review Kateryna Tymruk-Skoropad 1 , Iuliia Pavlova 1 , Svitlana Stupnytska 2 1. Lviv State University of Physical Culture 2. International University of Economics and Humanities academician Stepan Demianchuk DOI: Online publish date: 2019/12/30 Get citation AMA Tymruk-Skoropad K, Pavlova I, Stupnytska S. Educational component in rehabilitation programs for persons with chronic obstructive pulmonary disease: a systematic review. Advances in Rehabilitation. 2019;33(4):51-65. doi:10.5114/areh.2019.89827

2019 Advances in Rehabilitation

140. Tonifying kidney, lung, and spleen combined with western medicine for stable chronic obstructive pulmonary disease: A systematic review Full Text available with Trip Pro

Publication 03-Dec-2019 Correspondence Address : Prof. Zhen Gao Huashan Hospital, Fudan University, Shanghai 200433 China Source of Support: None, Conflict of Interest: None DOI: 10.4103/wjtcm.wjtcm_17_19 Abstract Introduction: This study aimed to evaluate the clinical effectiveness and safety of tonifying kidney, lung, and spleen ( TKLS ) combined with Western medicine for stable chronic obstructive pulmonary disease (COPD). Materials and Methods: Randomized controlled trials (RCTs) of TKLS for stable (...) for stable chronic obstructive pulmonary disease: A systematic review. World J Tradit Chin Med 2019;5:202-13 How to cite this URL: Liu YY, Gao Z. Tonifying kidney, lung, and spleen combined with western medicine for stable chronic obstructive pulmonary disease: A systematic review. World J Tradit Chin Med [serial online] 2019 [cited 2021 Feb 1];5:202-13. Available from: Introduction Chronic obstructive pulmonary disease (COPD) has been a major public health problem in the 21 st century, which imposes

2019 World Journal of Traditional Chinese Medicine